期刊文献+

端粒酶和mdm2基因蛋白在膀胱癌组织中的表达及其临床意义

EXPRESSION OF THE TELOMERASE AND mdm2 PROTEIN IN TISSUES OF BLADDER CANCER AND THEIR CLINICAL SIGNIFICANCE
下载PDF
导出
摘要 目的 检测膀胱癌组织中端粒酶及mdm2基因表达并探讨其临床意义。方法 用免疫组织化学技术 (SP法 )检测 38例膀胱组织标本中端粒酶及mdm2基因蛋白表达。结果 端粒酶在G1和Tis- 1肿瘤中阳性表达率分别低于在G2 +G3和T2 - 4中的阳性表达率 ,初发组阳性表达率低于复发组 (P <0 .0 5)。mdm2基因蛋白在Tis- 1肿瘤中阳性表达率显著高于T2 - 4中阳性表达率 (P<0 .0 5) ,初发组中阳性表达率高于复发组中阳性表达率 (P <0 .0 5)。随着病理分级及临床分期的增高 ,端粒酶阳性表达率逐渐增高 ,而mdm2基因蛋白阳性表达率逐渐下降。端粒酶阳性表达与患者术后生存率无关 ,mdm2阴性表达的病例生存率较低。结论 端粒酶染色阳性与mdm2基因蛋白的异常表达与肿瘤的发生及发展有关 ,两者表达均可作为判定膀胱肿瘤恶性程度的重要指标 。 Objective To investigate the expression of telomerase and mdm2 gene in tissues of bladder cancer and evaluate its clinical significance. Methods It was studied by means of immunohistochemical method in frozen section of tissues in 38 patients with bladder cancer. Results 24 of 38(63.16%)case showed positive telomerase staining,while none of the normal bladder tissues showed telomerase staining.The positive rate of telomerase staining in grade G1 was significantly lower than that in grade G2+G3.The rate in stage Tis-1 was significantly lower than that in stage T2-4,The positive rate in primary tumors was significantly lower than that in recurrence.The positive rate in mdm2 nuclear stain was 55.26%(21/38).The positive rate in stage Tis-1 was significantly higher than that in T2-4.Moreover,the positive rate in mdm2 was decreased with the increase of the tumor grades(P<0.05).The positive rate in primary tumors was significantly higher than that in recurrence.The staining of normal bladder tissues showed negative. Conclusion Expression of telomerase and mdm2 gene protein may be involved in tumorigenesis and tumor progression in urotholied neoplasia.They are both important markers for judging the malignancy and prognosis of bladder cancer.
出处 《中国煤炭工业医学杂志》 2002年第2期102-105,共4页 Chinese Journal of Coal Industry Medicine
关键词 临床意义 膀胱癌 免疫组织化学 端粒酶 MDM2基因 Bladder Cancer Immunohistochemistry Telomerase mdm2 gene
  • 相关文献

参考文献2

二级参考文献10

  • 1Simon KM.Design and conduct of clinical trials.In:Devita,Jr,VT. Hellman S,Kosenkerg SA.Cancer.Principles and Practice of Oncology. Vol1.Lippincott,Philadelphia,Third Edition,PP396-420.
  • 2Fakharzadch SS,Tursko SP,George DL.Tu-morigenic protential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.EMBO J,1991,10:1565.
  • 3Picksley SM,Vojtesek B,Sparks A,et al,Immunochemical analysis of the interaction of P53 with mdm2;fine mapping of the mdm2 binding site on P53 using synthetic peptides.Oncogene,1994.9:2523.
  • 4Leng P,Brown DR,Shivakumar CV,et al.Nterminal 130 amino acids of mdm2 are sufficient to inhibit P53-medlated transcriptional activation. Oncogene,1995,10:1275.
  • 5Barak Y,Gottlieb E,Juven-Gershon T,et al.Regulation of mdm2 expression by P53:alternative promoters produce transcripts with nonidentical translation protential.Genes & Development,1994,8:1739.
  • 6Haines DS,Landers JE,Engle LJ,et al.Physical and functional interaction between wild-type P53 and mdm2 proteins.Mol Cell Biol,1994,14:1171.
  • 7Lane DP.P53 guardian of the genoma.Nature,1992,358:15.
  • 8Oliner JD,Kinzler KW.Meltzer PS,et al.Amplification of a gene encoding a P53-associated protein in human sarcomas.Nature,1992,358:80.
  • 9Fujimoto K,Yameta Y,Orajima F,et al.Frequent association of P53 gene matation in invasive bladder cancer.Cancer Res,1992,52:1393.
  • 10Lianes P,Oriow I,Zhang IF,et al.Altered patterns of mdm2 and P53 expression in human bladder cancer.J Natl Cancer Inst,1994,86:1325.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部